Rasonque Approved: KRAS Inhibitor Doubles Survival to 13.2 Months

For drug developers and investors, the approval of Rasonque marks the first clinical validation of a multi-RAS(ON) inhibitor against the most common oncogenic driver in pancreatic tumors. The near-doubling of survival to 13.2 months, coupled with a cleaner safety profile than chemo, positions Revolution Medicines to compete in a high-unmet-need market while reshaping the KRAS inhibitor pipeline.

On August 26, 2026, the U.S. Food and Drug Administration approved daraxonrasib, to be sold under the brand name Rasonque by Revolution Medicines, for the treatment of metastatic pancreatic cancer. The approval is a landmark event: a late-stage clinical trial involving 500 patients demonstrated that the daily oral pill nearly doubled median overall survival compared with standard chemotherapy. Specifically, patients receiving daraxonrasib achieved a median survival of 13.2 months, versus 6.6 months among those on chemotherapy. ABC News reported the median survival for the experimental arm as "more than 13 months" while noting the chemo comparator was approximately 6.7 months, consistent with the nearly two-fold improvement.

“

In the pivotal trial, about 44% of patients on daraxonrasib experienced severe side effects, compared with 57.5% of patients treated with chemotherapy.

Pancreatic cancer has long been one of the most lethal malignancies, with roughly 67,000 new diagnoses annually in the United States and the highest mortality rate of all major cancers. More than half of patients die within three months of diagnosis, largely because the disease is typically detected at late stages and has historically had limited treatment options. Pancreatic adenocarcinoma accounts for about 3.2% of all cancer diagnoses but a disproportionately high share of cancer deaths. Against this backdrop, the approval of a targeted therapy that interferes with a core oncogenic driver—rather than relying on traditional chemotherapy—represents a significant shift.

Daraxonrasib works by locking onto and shutting off the mutated KRAS gene, a member of the RAS family of proteins that drives tumor growth in more than 90% of pancreatic tumors. This is notable because KRAS was long considered "undruggable," and the approval validates years of research into direct RAS inhibition. The drug's mechanism targets multiple forms of the RAS protein, potentially broadening its utility across RAS-driven cancers beyond pancreatic tumors. Dr. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at the Dana-Farber Cancer Institute, called the approval "an exceptional moment for patients with pancreatic cancer" and the culmination of years of research to target KRAS, adding that it brings "a new treatment option and new hope."

The regulatory pathway underscores the urgency and the strength of the data. The FDA granted daraxonrasib Breakthrough Therapy designation in June 2025, a status reserved for serious conditions where preliminary evidence suggests substantial improvement over available therapies. The agency reviewed the application under the Commissioner's National Priority Voucher Program and ultimately approved the drug six months ahead of the regulatory deadline. Angelo de Claro, director of the FDA's Oncology Center of Excellence, said the agency acted because the drug "showed unprecedented results in an area of high unmet need."

Safety data also favor the new therapy in some respects. The most common side effects were rash, diarrhea, nausea, fatigue, and vomiting. In the pivotal trial, about 44% of patients on daraxonrasib experienced severe side effects, compared with 57.5% of patients treated with chemotherapy. This improved tolerability could be meaningful for a patient population that is often frail and has limited reserve for aggressive therapy, although rash and gastrointestinal events will require proactive management.